Licaminlimab (OCS-02) — Topline data
Late 2026
With Licaminlimab PREDICT-1 trial site activations complete and a third of patients enrolled, we expect to report topline results around year-end.Source filing
OCS biotech catalysts & pipeline
OCULIS HOLDING AG · Data as of 2026-09-08
Upcoming catalysts
OCS-01 — NDA/BLA submission
Q4 2026
The topline results from both DIAMOND Phase 3 trials are expected in June 2026, with a subsequent New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) planned for Q4 2026 following a positive readout.Source filing
Privosegtor — IND submission
Q4 2026
Investigational New Drug (IND) submission being prepared for Q4 2026Source filing